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The aim of this multicentre, randomized study was to compare the ecacy and safety of moxifloxacin (BAY 12-
8039), a new 8-methoxy fluoroquinolone, with that of cefuroxime axetil for the treatment of acute bacterial sinusitis
in adults. Diagnosis was made on a range of clinical signs and symptoms combined with radiology and
microbiology.
A 400 mg dose of moxifloxacin was administered once daily for 7 days to 242 patients and 250 mg twice daily of
cefuroxime axetil was administered to 251 patients for 10 days. The clinical success rate at the end of treatment in
the evaluable population was significantly higher (967%) in the moxifloxacin group (204/211) than in the
cefuroxime axetil group (204/225, 907%; 95% confidence intervals 15%; 106%). At follow-up the success rate in
the moxifloxacin group was 907% and that for the cefuroxime axetil group was 892% (95% confidence intervals
743%; 54%). The predominant pathogens isolated were Streptococcus pneumoniae and Haemophilus influenzae,
followed byMoraxella catarrhalis and Staphylococcus aureus. The bacteriological eradication rates were higher for
moxifloxacin (945%, 103/109) than for cefuroxime axetil (835%, 96/115; 95% CI 36%; 197%). Only one S.
pneumoniae infection persisted following moxifloxacin therapy in contrast with three in individuals on cefuroxime
axetil. There were slightly more adverse events in the moxifloxacin group than in the cefuroxime axetil group, but
there were fewer serious adverse events following moxifloxacin treatment (three vs. eight). The drug was
discontinued because of adverse events in 14 moxifloxacin patients and in 11 cefuroxime axetil patients.
Overall, in all assessments, moxifloxacin was at least as eective clinically and bacteriologically, and as well
tolerated, as cefuroxime axetil in the treatment of acute sinusitis.
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Acute bacterial sinusitis is a common infection of one or
more of the paranasal sinuses. It frequently occurs as a
complication of a cold or other viral infection of the upper
respiratory tract (1,2,3). Repeated episodes of acute
sinusitis in untreated or inadequately treated patients can
lead to irreversible changes and chronic sinusitis. Early
diagnosis and eective antimicrobial therapy is thought to
be important for the prevention of such complications
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Germany.0954-6111/00/040337+08 $35?00/0(2,4). Accurate diagnosis based on clinical grounds can be
dicult and needs to be combined with techniques such as
radiography, ultrasonography or computer tomography
and by microbiological culture (4,5,6). Common symptoms
are post-nasal purulent discharge, facial pain, hyposmia,
jaw pain and nasal congestion (4,6,7)
Streptococcus pneumoniae and Haemophilus influenzae
usually account for at least 50% of bacterial pathogens
in patients with acute bacterial sinusitis (1,5,7,8). Staphy-
lococcus aureus, Moraxella catarrhalis and Streptococcus
pyogenes can also be important but less frequent pathogens.
Anaerobic and Gram-negative organisms are more rarely
involved (2,7,8).
Empiric therapy with penicillins has been the standard
for many years. However, the increasing frequency of b-
lactamase-producing strains of H. influenzae, S. aureus and# 2000 HARCOURT PUBLISHERS LTD
338 R. SIEGERT ET AL.M. catarrhalis and the spread of strains of S. pneumoniae
with reduced susceptibility to penicillins (1,9–11) has led to
the use of a wider range of antibacterial agents to combat
this reduction in sensitivity. Resistance to macrolides has
also increased in recent years, reducing the therapeutic
options for respiratory tract infections (9,10). Ideally the
therapeutic agent should be eective against the more
commonly occurring organisms. Many current agents need
to be administered more than once a day, usually for 10
days, and this can lead to problems with compliance
(12,13).
Moxifloxacin (BAY 12-8039) is a new 8-methoxyfluor-
oquinolone, developed by Bayer AG in Wuppertal and
Leverkusen, Germany. It shows improved activity against
Gram-positive organisms compared with earlier fluoroqui-
nolones, whilst retaining activity against Gram-negative
organisms (14,15). The compound is a pure enantiomer and
is chemically stable. Moxifloxacin shows advantages in
activity against a number of important species of Gram-
positive bacteria in vitro compared with other fluoroquino-
lones, including ofloxacin, levofloxacin and sparfloxacin,
and is similar in activity to ciprofloxacin against Gram-
negative organisms, with the exception of Pseudomonas
aeruginosa (15,16). There are indications that Gram-
positive organisms are less prone to acquire resistance
against moxifloxacin than against older fluoroquinolones
(16).
Moxifloxacin is well absorbed orally, with a long half-life
and high volume of distribution (17) and recent studies
have shown that it has particularly good activity against S.
pneumoniae, H. influenzae and M. catarrhalis, organisms
important in respiratory and sinus infections (18). Moxi-
floxacin may thus represent a significant improvement over
currently available oral antibiotics, including b-lactams,
macrolides and other fluoroquinolones. Its broad spectrum
of activity in vitro, including activity against drug-resistant
pathogens, should prove valuable, especially for empiri-
cally-based treatment regimens (14,16). This would include
infections of the respiratory tract which are caused by the
community-acquired pathogens referred to above. In
addition, moxifloxacin has activity against other respira-
tory pathogens such as Chlamydia, Legionella and Myco-
plasma species (14,15).
Cefuroxime-axetil was chosen as the control in this study
because of its known activity against the pathogens most
commonly found in acute bacterial sinus infections, its high
stability against various b-lactamases and its general
acceptance by the medical community as a therapy for
sinusitis (19).
Materials and methods
STUDY DESIGN
This was a prospective, randomized, double-blind, Phase
III clinical trial carried out in 60 centres in seven countries.
The safety and ecacy of moxifloxacin, at a dose of 400 mg
once daily for 7 days was compared with that of cefuroximeaxetil, at a dose of 250 mg twice daily for 10 days, in the
treatment of adult patients with acute bacterial sinusitis.
The study protocol was prepared in accordance with the
European Guide for Good Clinical Practice and national
and regional regulations, and was reviewed by all appro-
priate national and regional ethical committees.
PATIENTS
The subjects were outpatient adults of either sex, aged 18 or
over, with acute bacterial sinusitis. Sinusitis was diagnosed
either bacteriologically or clinically on the basis of
radiological paranasal sinus X-ray together with two or
more of the following symptoms; nasal congestion, post-
nasal drainage, frequent coughing or throat clearing,
frontal headache, malar tenderness or pain and purulent
nasal discharge.
Females of child-bearing age had to be using a reliable
contraceptive method. Subjects with a history of hypersen-
sitivity to either of the study drugs or related compounds
were excluded, as were those who had received any systemic
antibacterial therapy within 48 h of enrolment, or those
requiring concomitant systemic antibacterial treatment.
Subjects with a history of chronic sinusitis or previous
sinus surgery, or with two or more documented acute
sinusitis episodes within the previous 6 months were
excluded. Other exclusion criteria included neutropenia,
liver disease or renal insuciency, AIDS, any severe
infection or severe cardiac failure, a history of tendinopathy
with fluoroquinolones and pregnancy or lactation in
women. Written informed consent was obtained from all
patients prior to inclusion.
Details of all concomitant medications (mostly nasal
decongestants or mucolytic drugs) were recorded. Systemic
or topical corticosteroid administration was not allowed
during the study. Antacids were only allowed up to 2 h
prior to and after 4 h following drug intake.
TREATMENT
A total of 498 patients were recruited from centres in
Finland, France, Germany, Greece, Israel, Spain and
Sweden, 493 of whom were randomized to receive treat-
ment. Moxifloxacin was administered as a 400 mg capsule
each morning and a placebo capsule in the evening for
7 days to 242 patients. To ensure blinding, the patients
in the moxifloxacin group received two placebo capsules
from days 8–10. Cefuroxime axetil was administered to
251 patients as two daily capsules of 250 mg for
10 days. Compounds were taken orally with meals and
100 ml water.
EVALUATION
A full medical history was obtained before inclusion, and
the patients were examined clinically and an occipitomental
X-ray taken (Waters’ view). Sinus radiographs were graded
according to the degree of mucoperiosteal thickening,
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was collected for analysis and haematology. Samples were
collected for microbiological examination using three
dierent methods according to the preference of the
investigators. These were either a swab, collected under
endoscopic view, cannulation of the middle meatus or a
sinus puncture. Sinus puncture or aspiration was used by
most Scandinavian investigators, but also by some in
Germany, Southern Europe and Israel. Cannulation was
used in France, and swabs by a number of investigators in
Germany, Southern Europe and Israel.
A clinical assessment of progress was made and samples
of blood and urine collected between 7–9 days of treatment,
an end of treatment examination was made on day 14, and
a follow-up evaluation was made 27–31 days after the end
of treatment. Wherever possible, samples were collected for
microbiological examination again at the end of treatment
visit, and if patients had relapsed, again at the follow-up
visit. An additional X-ray at the end of treatment was
optional.
Overall clinical response was categorized as ‘resolution’,
‘improvement’, ‘failure’ or ‘indeterminate’, based on scor-
ing the signs and symptoms as ‘none’, ‘mild’, ‘moderate’ or
‘severe’. The clinical response was the primary ecacy
evaluation and the bacteriological response was a second-
ary end-point. Cultures collected before and after therapy
were used to assess response as ‘eradication’ where the
causative organism was not present at the end of therapy
and the patient was improved clinically. If no sample was
obtained in patients who had improved, eradication was
‘presumed’. ‘Persistence’ was where the causative organism
was still present at the end of therapy, and ‘presumed
persistence’ was where no sample was available and the
patient had not improved clinically. The presence of a
dierent pathogen during therapy or immediately after
therapy together with signs and symptoms of infection
requiring treatment with another antibacterial agent was
regarded as ‘superinfection’. Any non-evaluable response
was termed ‘indeterminate’.
Any adverse event was recorded, using COSTART terms
and definitions, and the patient observed closely until the
event had resolved or the patient’s condition had become
normal. Safety analysis was performed on all patients who
had received at least one dose of the study drug. The
incidence and severity of adverse events was noted and their
relationship to the drug administered assessed in accor-
dance with CIOMS III/ICH-4 as none, possible, probable
or not assessable.
STATISTICAL EVALUATION
The primary ecacy variable was the clinical response
in the patients completing therapy (evaluable population)
and the response in the two treatment groups was
compared by calculating a two-sided 95% confidence
interval for the dierence using Mantel–Haenszel weight-
ing. A dierence of more than 15% in the lower limit was
required to prove that moxifloxacin was no less eective
than the comparator.Results
BASELINE CHARACTERISTICS
The demographic and clinical characteristics, including the
presence of the six pre-specified clinical signs and symp-
toms, at baseline in both groups of the intent-to-treat (ITT)
population are listed in Table 1. The groups were well
balanced, with no major dierences being seen. Slightly
more patients were assessed as having a severe infection and
fewer a moderate infection at baseline in the moxifloxacin
group, than in the cefuroxime axetil group (P=007).
Slightly more patients in the cefuroxime axetil group had a
history of other diseases in addition to the sinusitis (506%
vs. 442%, P=016).
CLINICAL EVALUATION
Numbers evaluable for clinical ecacy were 211 of the 242
patients in the moxifloxacin group and 225 of the 251 in the
cefuroxime axetil group. The reasons for non-evaluability
did not dier significantly between the groups, and the
main reasons were insucient duration of therapy (21),
violation of inclusion or exclusion criteria (18) and essential
data missing (14).
The clinical responses at the end of treatment (day 14) in
both the ITT and evaluable groups are detailed in Table 2.
There was complete resolution of clinical symptoms in 89%
of the moxifloxacin group and 87% of the cefuroxime axetil
group in the ITT population, and in 967% and 907%
respectively in the evaluable population. The 95% con-
fidence intervals (15%; 106%) indicate that moxifloxacin
was not only as good as, but more eective than cefuroxime
axetil. Results at the follow-up of the clinical successes 21–
28 days after the end of therapy are detailed in Table 3, and
showed that 907% of patients treated with moxifloxacin
and 892% of those treated with cefuroxime axetil were still
assessed as successes. The number of relapses and patients
lost to follow-up were similar in each group. The 95%
confidence intervals were 743%; 54%, indicating no
significant dierence between the treatments.
MICROBIOLOGICAL EVALUATION
Cultures deemed to be pathogenic or ‘causative’ were
isolated from 257 of the 493 patients (521%) at baseline
and 224 of these were deemed to be evaluable for
microbiological ecacy (454%), 109 in the moxifloxacin
group and 115 in the cefuroxime axetil group. In the
majority of patients (202/257 or 786%) only one pathogen
was cultured, but in 46 patients (179%) there were two
pathogens and in nine patients (35%) there were three
pathogens isolated. The predominant causative organisms
were S. pneumoniae (96), H. influenzae (76), S. aureus (26)
andM. catarrhalis (25). Cannulation proved to be the most
eective method of obtaining positive bacterial cultures,
and swabs the least eective method, but these dierences
were small.
TABLE 1. Demographic and clinical characteristics of patients in the intent-to-treat population at baseline
Cefuroxime
Moxifloxacin axetil
Variable (n=242) (n=251) P value
Demographic Characteristics (number of patients)
Sex male 109 111 083
female 133 140
Age (years)* 404+146 403+141 095
Weight (kg)* 705+150 695+136 039
Clinical Characteristics (number of patients)
Severity of present infection (by investigator) mild 15 12 0016
moderate 122 158
severe 105 81
Number of sinuses involved 42 202 217 031
42 40 34
Frontal headache none 57 59 034
mild 41 47
moderate 74 89
severe 70 56
Malar tenderness/pain none 48 44 060
mild 35 47
moderate 108 112
severe 51 48
Nasal congestion none 8 11 065
mild 31 35
moderate 117 128
severe 86 77
Post-nasal drainage or discharge none 36 40 083
mild 58 52
moderate 105 115
severe 43 44
Cough/throat clearing none 77 95 022
mild 65 71
moderate 81 63
severe 19 22
Purulent nasal drainage none 19 27 040
mild 49 39
moderate 119 122
severe 55 63
History of other disease 107 (442%) 127 (506%) 0.16
*(Mean+standard deviation or frequencies)
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in Table 4. Bacterial success was taken as a combination of
eradication and presumed eradication and was high in both
groups. There were only six failures in the moxifloxacin
group and 19 in the cefuroxime axetil group. Failures
included those patients in whom the original infecting
organism was eradicated, but which was replaced by
another pathogen (superinfection). The 95% confidence
intervals indicated a significant dierence, with moxiflox-
acin being better than cefuroxime axetil. The clinicalassessment of these patients who were evaluable micro-
biologically showed a higher success rate for the moxi-
floxacin group, 103/109 (945%) compared with 96/115
(835%) in the cefuroxime axetil group.
The details of the eradication or persistence of the four
major pathogens is given in Table 5. Three patients
receiving cefuroxime axetil had a persistent S. pneumoniae
infection and five patients a persistent H. influenzae
infection. The corresponding numbers for patients treated
with moxifloxacin were only one of each. Other organisms
TABLE 3. Clinical responses at follow-up in patients treated sucessfully
Moxifloxacin Cefuroxime axetil
Clinical response (n=204) (n=204) 95% CI
Success 185 (907%) 182 (892%) 743%; 54%
Relapses 12 (59%) 13 (64%)
Lost to follow-up 4 (20%) 5 (25%)
Indeterminate 3 (15%) 4 (20%)
TABLE 4. Bacteriological evaluation at the end of treatment in evaluable population
Moxifloxacin Cefuroxime axetil
(n=109) (n=115) 95% CI
Bacteriological success 103 (945%) 96 (835%) 36%; 197%
Eradication 41 (376%) 33 (287%)
Presumed eradication 62 (569%) 63 (548%)
Bacteriological failure 6 (55%) 19 (165%)
Eradication with superinfection 2 (18%) 7 (61%)
Persistence plus with superinfection 2 (18%) 7 (61%)
Presumed persistence 2 (18%) 5 (43%)
TABLE 5. Response of major pathogens to treatment with moxifloxacin or cefuroxime axetil and susceptibility in vitro
Organism Treatment n Eradication Persistence MIC mg/I*
Streptococcus pneumoniae Moxifloxacin 39 38 (974%) 1 (26%) 0125
Cefuroxime axetil 48 45 (938%) 3 (62%) 0016
Haemophilus influenzae Moxifloxacin 29 28 (966%) 1 (34%) 0032
Cefuroxime axetil 35 30 (857%) 5 (143%) 10
Moraxella catarrhalis Moxifloxacin 14 14 (100%) 0 (0%) 0064
Cefuroxime axetil 9 8 (889%) 1 (111%) 0.5
Staphylococcus aureus Moxifloxacin 9 8 (889%) 1 (111%) 0064
Cefuroxime axetil 12 10 (833%) 2 (167%) 10
*Median MIC values of all strains isolated. Eradication and persistence includes presumed.
TABLE 2. Clinical response in the intent-to-treat (ITT) and evaluable population at the end of treatment
Moxifloxacin Cefuroxime axetil
Clinical response (n=242) (n=251) 95%CI
ITT population
Resolution 216 (893%) 219 (873%)
Failure 11 (46%) 22 (88%) 737%; 78%
Indeterminate 9 (37%) 7 (28%)
Missing 6 (25%) 3 (12%)
Evaluable population (n=211) (n=225)
Resolution 204 (967%) 204 (907%) 15%; 106%
Failure 7 (33%) 21 (93%)
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TABLE 6. Summary of all adverse events in intent-to-treat
population (by patient)
Moxifloxacin Cefuroxime axetil
(n=242) (n=252)
Any adverse 105 (434%) 88 (351%)
event (AE)
Any drug-related AE 74 (306%) 56 (223%)
Any serious AE 3 (12%) 8 (32%)
Discontinuation 14 (58%) 11 (44%)
because of AE
TABLE 7. Adverse events with at least a remote relationship
to the drug administered (intent-to-treat population)
Moxifloxacin Cefuroxime axetil
(n=242) (n=251)
Diarrhoea 23 (95%) 15 (60%)
Abdominal pain 10 (41%) 7 (28%)
Nausea 9 (37%) 5 (20%)
Vomiting 8 (33%) 4 (16%)
Vertigo 7 (29%) 2 (08%)
342 R. SIEGERT ET AL.not eradicated were one Proteus mirabilis and two
Pseudomonas aeruginosa in the moxifloxacin group and
one Staphylococcus epidermidis and two Streptococcus spp.
in the cefuroxime axetil group. The median MIC values
for each drug against the four species are also included in
Table 5. These values are for all strains isolated in the
study, not just the organisms isolated from the evaluable
patients. Cefuroxime axetil was less active than moxiflox-
acin against all but the pneumococci. When persistent
organisms were cultured at the end of treatment, they were
still susceptible to the drug administered, with the exception
of a strain of S. aureus where the MIC of cefuroxime axetil
increased from 05 mg l71 pre-therapy to 40 mg l71 post-
therapy.
SAFETY EVALUATION
All patients who received at least one dose of drug, that is
the ITT population (n=493), were included in the safety
assessment. Table 6 summarizes the total incidence of
adverse events and indicates whether they were drug-
related, serious, and whether they led to treatment being
discontinued. There were more patients with drug-related
adverse events in the group receiving moxifloxacin (31% vs.
22%), but fewer of these drug-related events were serious
(0% vs. 2%). These dierences were not statistically
significant. None of the serious events occurring in the
moxifloxacin group were regarded as drug-related, whereas
three serious events occurring in two patients treated with
cefuroxime axetil were believed to be drug-related. Therewere a similar number of withdrawals because of an adverse
event in both groups. The type of adverse events that were
drug-related are listed in Table 7. This includes probably
and possibly drug-related events. The most common
adverse event in each group was diarrhoea, with abdominal
pain, nausea and vomiting being less frequent. All adverse
events occurring in both groups resolved satisfactorily.
Laboratory analysis of serum and urine samples showed no
clinically related dierences between the two groups.
Discussion
Although some controversy exists over the necessity for
treatment of acute bacterial sinusitis (20,21) most would
accept that when diagnosed properly, treatment should be
given to prevent both the development of chronic sinusitis
or rarer complications (4,5,21). Considerable care was given
in this study in the diagnosis of sinusitis. Distinguishing
between acute sinusitis and rhinitis can be dicult,
especially when using physical examination only (20), but
in this study ear, nose and throat (ENT) specialists were
used who have greater experience than general practitioners
in diagnosing this condition. In addition to several clinical
signs and symptoms needing to be present, radiology
was used and bacteriological sampling was performed.
The single Waters’ radiographical view was chosen;
this is widely used because it is simple to perform and
relatively cheap. It has been criticised by some as not being
as sensitive a diagnostic tool as three or four view
radiographs (22) or CT scans (23). However, these and
other studies do show that the Waters’ view is a good
diagnostic tool for the commonest form of sinusitis, namely
maxillary sinusitis, comparing favourably with other
methods, particularly when combined with other ap-
proaches and when used by ENT specialists, such as in
this study (22–24).
Bacterial cultures were collected by three methods,
cannulation, aspiration and swabs, depending on the local
clinicians’ practice. The numbers of patients with positive
cultures were high for this type of study (450%) and this
indicates both the accuracy of the diagnosis and the
adequacy of the sampling technique. The predominant
pathogens were S. pneumoniae and H. influenzae, with the
next most prevalent organisms being M. catarrhalis and S.
aureus. This is in agreement with most studies on the
aetiology of acute bacterial sinusitis (1,5,7,8).
This was a multicentre, randomized prospective trial in
adults with acute bacterial sinusitis and was designed to
compare the ecacy and safety of moxifloxacin with
cefuroxime axetil. Cefuroxime axetil has been widely used
in such infections as it has greater stability to b-lactamases
than amoxycillin. Its use in sinusitis has been summarized
by Pakes et al. (19). A dose of 400 mg of moxifloxacin was
given once daily for 7 days to 242 patients in contrast with a
twice daily dose of 250 mg of cefuroxime axetil given to 251
patients for 10 days.
The statistical evaluation showed that the success rate in
the evaluable patients at the end of treatment was
significantly higher for moxifloxacin (967%) and the
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and 93% respectively). The results at follow-up also
showed that moxifloxacin was at least as eective as
cefuroxime axetil. The bacteriological eradication rate was
higher with moxifloxacin (945%) than with cefuroxime
axetil (835%).
An interesting point was the failure of cefuroxime axetil
to eradicate three of the pneumococcal infections in spite of
having lower MICs than moxifloxacin against these strains.
Moxifloxacin has excellent penetration into cells and
tissues, resulting in levels in excess of the MIC value at
the site of infection, and this good penetration could
account for the high rate of eradication of pneumococcal
infections. A recent study by Andrews et al. (25) showed
that following a single oral dose of 400 mg, moxifloxacin
penetrated into the respiratory tree in high levels. Levels in
alveolar macrophages remained above 10 mg l71 for over
24 h post-dosing. In addition, Stass et al. (17) have shown
that moxifloxacin penetrates into saliva with levels persist-
ing for more than 24 h after a single dose.
The good tissue penetration of moxifloxacin resulting in
high concentrations at the site of infection, may become
increasingly important with the spread of antibiotic-
resistant strains. Resistance to macrolides in pneumococci
has increased in Europe in recent years more than in the
U.S.A., and this has been associated with the increased use
of macrolides in Europe (9). Similarly, penicillin-resistance
has been linked not just to penicillin use, but to overall use
of b-lactams, and particularly to an increase in cephalos-
porin use (9). There is also some evidence that low levels of
b-lactams dosed for a long period can increase the
possibility of the development of low-level resistance
(26,27). In this context, there is much interest in the use
of shorter courses of therapy (27). In this study, a 7-day
course was used rather than the more widely used 10-day
course of therapy. Moxifloxacin, with its long half-life and
good tissue penetration is eminently suitable for such a
dosing regimen.
This study has shown that moxifloxacin compares
favourably with cefuroxime axetil in the treatment of acute
bacterial sinusitis in adults both in clinical and bacteriolo-
gical ecacy and in safety. The simple once-daily, short
course, dosing regimen oers advantages over many
existing agents and can increase compliance. Good activity
has been reported against a wide range of respiratory
pathogens, including many with resistance to b-lactams and
to other commonly used antibiotics. These factors indicate
that moxifloxacin may have utility in a range of respiratory
tract infections.
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